Clinical Trial Update: A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, pharmacodynamics, safety, and immunogenicity of FKS518 in postmenopausal osteoporosis has completed, and results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• FKS518

Snippet

Sponsor: Fresenius Kabi SwissBioSim GmbH | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-27